首页|LncRNA CCRR maintains Ca2+homeostasis against myocardial infarction through the FTO-SERCA2a pathway

LncRNA CCRR maintains Ca2+homeostasis against myocardial infarction through the FTO-SERCA2a pathway

扫码查看
Cardiac conduction regulatory RNA(CCRR)has been documented as an antiarrhythmic IncRNA in our earlier investigation.This study aimed to evaluate the effects of CCRR on SERCA2a and the associated Ca2+homeostasis in myocardial infarction(MI).Overexpression of CCRR via AAV9-mediated delivery not only partially reversed ischemia-induced contractile dysfunction but also alleviated abnormal Ca2+homeostasis and reduced the heightened methylation level of SERCA2a following MI.These effects were also observed in CCRR over-expressing transgenic mice.A conserved sequence domain of CCRR mimicked the protective function observed with the full length.Furthermore,silencing CCRR in healthy mice led to intracellular Ca2+overloading of cardiomyocytes.CCRR increased SERCA2a protein stability by upregulating FTO expression.The direct interaction between CCRR and FTO protein was characterized by RNA-binding protein immunoprecipitation(RIP)analysis and RNA pulldown experiments.Activation of NFATc3 was identified as an upstream mechanism responsible for CCRR downregulation in MI.This study demonstrates that CCRR is a protective IncRNA that acts by maintaining the function of FTO,thereby reducing the m6A RNA methylation level of SERCA2a,ultimately preserving calcium homeostasis for myocardial contractile function in MI.Therefore,CCRR may be considered a promising therapeutic strategy with a beneficial role in cardiac pathology.

CCRRcalcium homeostasisFTOmyocardial infarctionSERCA2a

Hua Yang、Lina Xuan、Shengjie Wang、Huishan Luo、Xiaomeng Duan、Jianjun Guo、Shijia Cui、Jieru Xin、Junwei Hao、Xiufang Li、Jun Chen、Feihan Sun、Xiaolin Hu、Siyun Li、Ying Zhang、Lei Jiao、Baofeng Yang、Lihua Sun

展开 >

Department of Pharmacology,Harbin Medical University(State Key Laboratory of Frigid Zone Cardiovascular Disease,the State-Province Key Laboratories of Biomedicine-Pharmaceutics of China,Key Laboratory of Cardiovascular Research,Ministry of Education,Joint International Research Laboratory of Cardiovascular Medicine Research,Ministry of Education,China),College of Pharmacy,Harbin Medical University,Harbin 150081,China

National Natural Science Foundation of ChinaNational Natural Science Foundation of ChinaNational Natural Science Foundation of ChinaNatural Science Foundation of Heilongjiang Province,ChinaOutstanding Young Talent Research Fund of College of Pharmacy,Harbin Medical University2021(the second batch)Research Funds for affiliated research institutes in Heilongjiang Province

8197020281903609U21A20339LH2022H0022019-JQ-02CZKYF2021-2-C013

2024

中国科学:生命科学(英文版)
中国科学院

中国科学:生命科学(英文版)

CSTPCD
影响因子:0.806
ISSN:1674-7305
年,卷(期):2024.67(8)